articleThe LancetMar 1, 2009GREEN OA

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

RPRonald P. DeMatteoKVKarla V. BallmanCRCristina R. AntonescuRGRobert G. MakiPWPeter W. T. Pisters

Memorial Sloan Kettering Cancer Center · Mayo Clinic in Arizona · +10 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,358
total citations
FWCI
87.11
Percentile
100%
References
29
Citations per year

Authors

15

Topics & keywords

Topics
Keywords
  • Medicine
  • Imatinib mesylate
  • Imatinib
  • Placebo
  • Clinical endpoint
  • Interim analysis
  • Internal medicine
  • GiST
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding